Super Important Biotech and Drug Stock Events for November
BOSTON ( TheStreet) -- The November calendar of biotech and drug stock events.
Nov. 3
Earnings: Arena Pharmaceuticals (ARNA) - Get Arena Pharmaceuticals Inc. Report , MannKind (MNKD) - Get MannKind Corporation ReportNeurocrine Biosciences (NBIX) - Get Neurocrine Biosciences Inc. Report
Nov. 4
Earnings: Ironwood Pharma (IRWD) - Get Ironwood Pharmaceuticals Inc. Report , Jazz Pharma (JAZZ) - Get Jazz Pharmaceuticals plc Report , Halozyme Therapeutics (HALO) - Get Halozyme Therapeutics Inc. Report , Exelixis (EXEL) - Get Exelixis Inc. Report , Myriad Genetics (MYGN) - Get Myriad Genetics Inc. Report , Pharmacylics (PCYC) , Regeneron Pharma (REGN) - Get Regeneron Pharmaceuticals Inc. Report
FDA releases briefing documents for Oncologic Drug Advisory Committee meeting scheduled for Nov. 6: Rockwell Medical (RMTI) - Get Rockwell Medical Inc. Report (Triferic) and Novartis (NVS) - Get Novartis AG Report (Faridak.)
Nov. 5
Earnings: Actavis (ACT) - Get Enact Holdings Inc. ReportRegulus Therapeutics (RGLS) - Get Regulus Therapeutics Inc. Report , Vivus (VVUS) - Get VIVUS, Inc. Report , Alnylam Pharma (ALNY) - Get Alnylam Pharmaceuticals Inc. Report
FDA approval decision: Aeterna Zentaris (AEZS) - Get Aeterna Zentaris Inc. Report Macrilen for growth hormone deficiency.
The Medicines Co. (MDCO) - Get Medicines Company Report Investor/Analyst meeting.
Nov. 6
Earnings: Amarin (AMRN) - Get Amarin Corporation plc Report , AstraZeneca (AZN) - Get AstraZeneca PLC Report , Epizyme (EPZM) - Get Epizyme Inc. Report , Hyperion Therapeutics (HPTX) Keryx Pharma (KERX) - Get Keryx Biopharmaceuticals, Inc. Report , Medivation (MDVN) , NewLink Genetics (NLNK) - Get n.a. Report , Raptor Pharma (RPTP) , Tekmira Pharma (TKMR) , Spectrum Pharma (SPPI) - Get Spectrum Pharmaceuticals Inc. Report , Sarepta Therapeutics (SRPT) - Get Sarepta Therapeutics Inc. Report
FDA Oncologic Drugs Advisory Committee: Rockwell Medical (Triferic) and Novaris (Faridak.)
Nov. 7
Earnings: Agios Pharma (AGIO) - Get Agios Pharmaceuticals Inc. Report , Intercept Pharma (ICPT) - Get Intercept Pharmaceuticals Inc. Report
Nov. 10
TheStreet Recommends
Intercept Pharma Analyst/Investor Day.
Nov. 13
Earnings: Retrophin (RTRX) - Get Retrophin, Inc. Report
Nov. 18
AstraZeneca Analyst/Investor Day
Ligand (LGND) - Get Ligand Pharmaceuticals Incorporated Report Analyst/Investor Day
Nov. 19
FDA approval decision: Genentech/Roche (RHHBY) Avastin for recurrent, platinum-resistant ovarian cancer.
Nov. 26
FDA approval decision: Avanir Pharma (AVNR) AVP-825 for migraine.
November Medical Meetings:
Nov. 2-7: Obesity Week: Orexigen Therapeutics (OREX) , Arena Pharma ARNA
Nov. 7-11: American Association for the Study of Liver Disease (AASLD): Gilead Sciences (GILD) - Get Gilead Sciences Inc. Report , Merck (MRK) - Get Merck & Company Inc. Report , Bristol-Myers Squibb (BMY) - Get Bristol-Myers Squibb Company Report , Abbvie ABBV, Enanta Pharma (ENTA) - Get Enanta Pharmaceuticals Inc. Report , Arrowhead Research (ARWR) - Get Arrowhead Pharmaceuticals Inc. Report , Conatus Pharma (CNAT) - Get Conatus Pharmaceuticals Inc. Report , Genfit ALGFT, Alnylam Pharma (ALNY) - Get Alnylam Pharmaceuticals Inc. Report
Nov. 9: International Gynecologic Cancer Society: Oxigene (OXGN) fosbretabulin+Avastin phase II recurrent ovarian cancer.
Nov. 11-16: American Society of Nephrology: Acceleron Pharma (XLRN) - Get Acceleron Pharma Inc Report
Nov. 13-16: Society of Neuro-Oncology annual meeting: Celldex Therapeutics (CLDX) - Get Celldex Therapeutics Inc. Report , ImmunoCellular Therapeutics (IMUC)
Nov. 15-19: American Heart Association Scientific Sessions: Merck, NeoStem (NBS) , Regeneron Pharma
Nov. 18-21: EORTC-NCI-AACR: Agios Pharma, Bind Therapeutics (BIND) , Clovis Oncology
Clinical Data:
XOMA (XOMA) - Get XOMA Corporation Report Gevokizumab (Behcet's Syndrome), Achillion Pharma (ACHN) - Get Achison Inc Cl A Report ACH-3422 (hepatitis C)
Source: BioMedTracker.com, company reports and TheStreet research.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
